Cogent Biosciences (COGT) Competitors $8.00 -0.09 (-1.11%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$8.07 +0.07 (+0.83%) As of 02/21/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends COGT vs. ACLX, AKRO, RYTM, SRRK, IMVT, APLS, VKTX, ACAD, CRNX, and ZLABShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Arcellx (ACLX), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Crinetics Pharmaceuticals (CRNX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Arcellx Akero Therapeutics Rhythm Pharmaceuticals Scholar Rock Immunovant Apellis Pharmaceuticals Viking Therapeutics ACADIA Pharmaceuticals Crinetics Pharmaceuticals Zai Lab Arcellx (NASDAQ:ACLX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Which has more risk & volatility, ACLX or COGT? Arcellx has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ACLX or COGT? 96.0% of Arcellx shares are owned by institutional investors. 6.2% of Arcellx shares are owned by insiders. Comparatively, 5.9% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor ACLX or COGT? In the previous week, Arcellx had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Arcellx and 3 mentions for Cogent Biosciences. Arcellx's average media sentiment score of 0.96 beat Cogent Biosciences' score of 0.65 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ACLX or COGT? Cogent Biosciences received 220 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 70.59% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformArcellxOutperform Votes6882.93% Underperform Votes1417.07%Cogent BiosciencesOutperform Votes28870.59% Underperform Votes12029.41% Is ACLX or COGT more profitable? Cogent Biosciences has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Arcellx's return on equity of -8.28% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-25.94% -8.28% -5.21% Cogent Biosciences N/A -112.55%-60.44% Do analysts rate ACLX or COGT? Arcellx currently has a consensus price target of $105.93, indicating a potential upside of 66.16%. Cogent Biosciences has a consensus price target of $14.33, indicating a potential upside of 79.17%. Given Cogent Biosciences' higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, ACLX or COGT? Arcellx has higher revenue and earnings than Cogent Biosciences. Arcellx is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$110.32M31.25-$70.69M-$0.71-89.79Cogent BiosciencesN/AN/A-$192.41M-$2.48-3.23 SummaryArcellx beats Cogent Biosciences on 13 of the 18 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$893.64M$7.05B$5.82B$9.13BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-3.236.1426.8119.20Price / SalesN/A267.62434.5471.83Price / CashN/A65.6738.0134.83Price / Book3.486.707.644.62Net Income-$192.41M$138.98M$3.19B$246.06M7 Day Performance-0.37%-2.63%-2.13%-2.63%1 Month Performance-10.01%-3.63%-1.11%-2.57%1 Year Performance7.53%-5.69%15.71%12.71% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences1.3565 of 5 stars$8.00-1.1%$14.33+79.2%-10.6%$893.64MN/A-3.2380Upcoming EarningsACLXArcellx2.0089 of 5 stars$65.23+2.4%$105.93+62.4%+5.4%$3.53B$155.82M-91.8780Upcoming EarningsAKROAkero Therapeutics4.3863 of 5 stars$50.52+2.6%$75.86+50.2%+114.1%$3.53BN/A-13.4730Insider TradeRYTMRhythm Pharmaceuticals4.0689 of 5 stars$56.69-1.5%$68.09+20.1%+27.3%$3.48B$77.43M-13.09140Upcoming EarningsAnalyst ForecastInsider TradeNews CoverageSRRKScholar Rock3.0544 of 5 stars$37.07-1.5%$40.43+9.1%+141.2%$3.47B$33.19M-15.77140Insider TradeNews CoveragePositive NewsIMVTImmunovant2.4886 of 5 stars$20.33+2.4%$45.90+125.8%-40.9%$3.45BN/A-7.76120APLSApellis Pharmaceuticals4.2199 of 5 stars$27.40-0.2%$46.71+70.5%-59.3%$3.41B$396.59M-13.50770Short Interest ↓VKTXViking Therapeutics4.3635 of 5 stars$30.48+3.3%$97.29+219.2%-4.5%$3.40BN/A-30.4820ACADACADIA Pharmaceuticals3.0806 of 5 stars$20.04+1.4%$24.00+19.8%-19.7%$3.33B$726.44M25.69510Upcoming EarningsShort Interest ↓CRNXCrinetics Pharmaceuticals4.1075 of 5 stars$35.21-0.1%$72.64+106.3%+2.1%$3.27B$4.01M-9.44210ZLABZai Lab2.5491 of 5 stars$29.00+0.6%$55.00+89.7%+68.2%$3.17B$266.72M-10.472,175Upcoming EarningsAnalyst RevisionNews CoverageGap Up Related Companies and Tools Related Companies Arcellx Alternatives Akero Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Scholar Rock Alternatives Immunovant Alternatives Apellis Pharmaceuticals Alternatives Viking Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Crinetics Pharmaceuticals Alternatives Zai Lab Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COGT) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COGT Stock Alerts